Advertisement
Advertisement

CYTK

CYTK logo

Cytokinetics Inc.

64.33
USD
Sponsored
+1.00
+1.59%
Jan 14, 14:50 UTC -5
Open

CYTK Earnings Reports

Positive Surprise Ratio

CYTK beat 14 of 39 last estimates.

36%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$6.54M
/
-$1.47
Implied change from Q3 25 (Revenue/ EPS)
+237.78%
/
-42.13%
Implied change from Q4 24 (Revenue/ EPS)
-61.37%
/
+16.67%

Cytokinetics Inc. earnings per share and revenue

On Nov 05, 2025, CYTK reported earnings of -2.54 USD per share (EPS) for Q3 25, missing the estimate of -1.61 USD, resulting in a -58.24% surprise. Revenue reached 1.94 million, compared to an expected 3.63 million, with a -46.62% difference. The market reacted with a +1.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 22 analysts forecast an EPS of -1.47 USD, with revenue projected to reach 6.54 million USD, implying an decrease of -42.13% EPS, and increase of 237.78% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
MapLight Therapeutics, Inc. Common Stock
Report Date
Jan 09, 2026 For Q3 25
Estimate
-$1.72
Actual
-$37.18
Surprise
-2054.36%
logo
Anixa Biosciences, Inc.
Report Date
Jan 12, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.09
Surprise
-0.78%
FAQ
For Q3 2025, Cytokinetics Inc. reported EPS of -$2.54, missing estimates by -58.24%, and revenue of $1.94M, -46.62% below expectations.
The stock price moved up 1.88%, changed from $59.19 before the earnings release to $60.30 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 22 analysts, Cytokinetics Inc. is expected to report EPS of -$1.47 and revenue of $6.54M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement